Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology                  
2    Executive Summary
3    Asia Pacific Anti-Obesity Drugs Market Overview 
    3.1    Asia Pacific Anti-Obesity Drugs Market Historical Value (2017-2023) 
    3.2    Asia Pacific Anti-Obesity Drugs Market Forecast Value (2024-2032)
4    Asia Pacific Anti-Obesity Drugs Market Landscape*
    4.1    Asia Pacific Anti-Obesity Drugs Market: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Asia Pacific Anti-Obesity Drugs Market: Product Landscape
        4.2.1    Analysis by Product    
        4.2.2    Analysis by Material
        4.2.3    Analysis by Type
5    Asia Pacific Anti-Obesity Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Analysis
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Asia Pacific Anti-Obesity Drugs Market Segmentation (2017-2032)
    6.1    Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Drugs 
        6.1.1    Market Overview
        6.1.2    Semaglutide  
        6.1.3    Phentermine/Topiramate  
        6.1.4    Naltrexone/Bupropion  
        6.1.5    Liraglutide  
        6.1.6    Gelesis 100  
        6.1.7    Orlistat  
        6.1.8    Phentermine  
        6.1.9    Methamphetamine  
        6.1.10    Tirzepatide   
    6.2    Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Drug Class
        6.2.1    Market Overview
        6.2.2    Amphetamine   
        6.2.3    GLP-1 receptor agonist 
        6.2.4    Lipase Inhibitor 
    6.3    Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action  
        6.3.1    Market Overview 
        6.3.2    Centrally Acting Drugs 
        6.3.3    Peripherally Acting Drugs  
    6.4    Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Route of Administration 
        6.4.1    Market Overview  
        6.4.2    Oral 
        6.4.3    Subcutaneous  
    6.5    Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Prescription Type  
        6.5.1    Market Overview 
        6.5.2    Prescription Drugs  
        6.5.3    Over The Counter Drugs   
    6.6    Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
        6.6.1    Market Overview
        6.6.2    Hospital Pharmacies  
        6.6.3    Drug Store & Retail Pharmacies  
        6.6.4    Online Pharmacies
    6.7    Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Countries
        6.7.1    Market Overview
        6.7.2    China 
        6.7.3    Japan
        6.7.4    ASEAN
        6.7.5    Australia 
        6.7.6    India
        6.7.7    Others
7    China Anti- Obesity Drugs Market (2017-2032)
    7.1    China Anti-Obesity Drugs Market (2017-2032) by Drugs 
        7.1.1    Market Overview
        7.1.2    Semaglutide  
        7.1.3    Phentermine/Topiramate  
        7.1.4    Naltrexone/Bupropion  
        7.1.5    Liraglutide  
        7.1.6    Gelesis 100  
        7.1.7    Orlistat  
        7.1.8    Phentermine  
        7.1.9    Methamphetamine  
        7.1.10    Tirzepatide   
    7.2    China Anti-Obesity Drugs Market (2017-2032) by Drug Class
        7.2.1    Market Overview
        7.2.2    Market Overview 
        7.2.3    Amphetamine   
        7.2.4    GLP-1 receptor agonist 
        7.2.5    Lipase Inhibitor 
    7.3    China Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action  
        7.3.1    Market Overview 
        7.3.2    Centrally Acting Drugs 
        7.3.3    Peripherally Acting Drugs  
    7.4    China Anti-Obesity Drugs Market (2017-2032) by Route of Administration 
        7.4.1    Market Overview  
        7.4.2    Oral 
        7.4.3    Subcutaneous  
    7.5    China Anti-Obesity Drugs Market (2017-2032) by Prescription Type  
        7.5.1    Market Overview 
        7.5.2    Prescription Drugs  
        7.5.3    Over The Counter Drugs   
    7.6    China Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
        7.6.1    Market Overview
        7.6.2    Hospital Pharmacies  
        7.6.3    Drug Store & Retail Pharmacies  
        7.6.4    Online Pharmacies 
8    Japan Anti- Obesity Drugs Market (2017-2032)
    8.1     Japan Anti-Obesity Drugs Market (2017-2032) by Drugs 
        8.1.1    Market Overview
        8.1.2    Semaglutide  
        8.1.3    Phentermine/Topiramate  
        8.1.4    Naltrexone/Bupropion  
        8.1.5    Liraglutide  
        8.1.6    Gelesis 100  
        8.1.7    Orlistat  
        8.1.8    Phentermine  
        8.1.9    Methamphetamine  
        8.1.10    Tirzepatide   
    8.2    Japan Anti-Obesity Drugs Market (2017-2032) by Drug Class
        8.2.1    Market Overview
        8.2.2    Market Overview 
        8.2.3    Amphetamine   
        8.2.4    GLP-1 receptor agonist 
        8.2.5    Lipase Inhibitor 
    8.3    Japan Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action  
        8.3.1    Market Overview 
        8.3.2    Centrally Acting Drugs 
        8.3.3    Peripherally Acting Drugs  
    8.4    Japan Anti-Obesity Drugs Market (2017-2032) by Route of Administration 
        8.4.1    Market Overview  
        8.4.2    Oral 
        8.4.3    Subcutaneous  
    8.5    Japan Anti-Obesity Drugs Market (2017-2032) by Prescription Type  
        8.5.1    Market Overview 
        8.5.2    Prescription Drugs  
        8.5.3    Over The Counter Drugs   
    8.6    Japan Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
        8.6.1    Market Overview
        8.6.2    Hospital Pharmacies  
        8.6.3    Drug Store & Retail Pharmacies  
        8.6.4    Online Pharmacies 
9    ASEAN Anti-Obesity Drugs Market (2017-2032)
    9.1    ASEAN Anti-Obesity Drugs Market (2017-2032) by Drugs 
        9.1.1    Market Overview
        9.1.2    Semaglutide  
        9.1.3    Phentermine/Topiramate  
        9.1.4    Naltrexone/Bupropion  
        9.1.5    Liraglutide  
        9.1.6    Gelesis 100  
        9.1.7    Orlistat  
        9.1.8    Phentermine  
        9.1.9    Methamphetamine  
        9.1.10    Tirzepatide   
    9.2    ASEAN Anti-Obesity Drugs Market (2017-2032) by Drug Class
        9.2.1    Market Overview
        9.2.2    Market Overview 
        9.2.3    Amphetamine   
        9.2.4    GLP-1 receptor agonist 
        9.2.5    Lipase Inhibitor 
    9.3    ASEAN Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action  
        9.3.1    Market Overview 
        9.3.2    Centrally Acting Drugs 
        9.3.3    Peripherally Acting Drugs  
    9.4    ASEAN Anti-Obesity Drugs Market (2017-2032) by Route of Administration 
        9.4.1    Market Overview  
        9.4.2    Oral 
        9.4.3    Subcutaneous  
    9.5    ASEAN Anti-Obesity Drugs Market (2017-2032) by Prescription Type  
        9.5.1    Market Overview 
        9.5.2    Prescription Drugs  
        9.5.3    Over The Counter Drugs   
    9.6    ASEAN Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
        9.6.1    Market Overview
        9.6.2    Hospital Pharmacies  
        9.6.3    Drug Store & Retail Pharmacies  
        9.6.4    Online Pharmacies 
10    Australia Anti-Obesity Drugs Market (2017-2032)
    10.1    Australia Anti-Obesity Drugs Market (2017-2032) by Drugs 
        10.1.1    Market Overview
        10.1.2    Semaglutide  
        10.1.3    Phentermine/Topiramate  
        10.1.4    Naltrexone/Bupropion  
        10.1.5    Liraglutide  
        10.1.6    Gelesis 100  
        10.1.7    Orlistat  
        10.1.8    Phentermine  
        10.1.9    Methamphetamine  
        10.1.10    Tirzepatide   
    10.2    Australia Anti-Obesity Drugs Market (2017-2032) by Drug Class
        10.2.1    Market Overview
        10.2.2    Market Overview 
        10.2.3    Amphetamine   
        10.2.4    GLP-1 receptor agonist 
        10.2.5    Lipase Inhibitor 
    10.3    Australia Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action  
        10.3.1    Market Overview 
        10.3.2    Centrally Acting Drugs 
        10.3.3    Peripherally Acting Drugs  
    10.4    Australia Anti-Obesity Drugs Market (2017-2032) by Route of Administration 
        10.4.1    Market Overview  
        10.4.2    Oral 
        10.4.3    Subcutaneous  
    10.5    Australia Anti-Obesity Drugs Market (2017-2032) by Prescription Type  
        10.5.1    Market Overview 
        10.5.2    Prescription Drugs  
        10.5.3    Over The Counter Drugs   
    10.6    Australia Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
        10.6.1    Market Overview
        10.6.2    Hospital Pharmacies  
        10.6.3    Drug Store & Retail Pharmacies  
        10.6.4    Online Pharmacies 
11    India Anti-Obesity Drugs Market (2017-2032)
    11.1    India Anti-Obesity Drugs Market (2017-2032) by Drugs 
        11.1.1    Market Overview
        11.1.2    Semaglutide  
        11.1.3    Phentermine/Topiramate  
        11.1.4    Naltrexone/Bupropion  
        11.1.5    Liraglutide  
        11.1.6    Gelesis 100  
        11.1.7    Orlistat  
        11.1.8    Phentermine  
        11.1.9    Methamphetamine  
        11.1.10    Tirzepatide   
    11.2    India Anti-Obesity Drugs Market (2017-2032) by Drug Class
        11.2.1    Market Overview
        11.2.2    Market Overview 
        11.2.3    Amphetamine   
        11.2.4    GLP-1 receptor agonist 
        11.2.5    Lipase Inhibitor 
    11.3    India Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action  
        11.3.1    Market Overview 
        11.3.2    Centrally Acting Drugs 
        11.3.3    Peripherally Acting Drugs  
    11.4    India Anti-Obesity Drugs Market (2017-2032) by Route of Administration 
        11.4.1    Market Overview  
        11.4.2    Oral 
        11.4.3    Subcutaneous  
    11.5    India Anti-Obesity Drugs Market (2017-2032) by Prescription Type  
        11.5.1    Market Overview 
        11.5.2    Prescription Drugs  
        11.5.3    Over The Counter Drugs   
    11.6    India Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
        11.6.1    Market Overview
        11.6.2    Hospital Pharmacies  
        11.6.3    Drug Store & Retail Pharmacies  
        11.6.4    Online Pharmacies 
12    Regulatory Framework
13    Patent Analysis
    13.1      Analysis by Type of Patent
    13.2      Analysis by Publication year
    13.3      Analysis by Issuing Authority
    13.4      Analysis by Patent Age
    13.5      Analysis by CPC Analysis
    13.6      Analysis by Patent Valuation 
    13.7      Analysis by Key Players
14    Funding and Investment Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6 Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1     Analysis by Partnership Instances
    15.2     Analysis by Type of Partnership
    15.3     Analysis by Leading Players
    15.4      Analysis by Geography
16    Supplier Landscape
    16.1    Market Share by Top 5 Companies
    16.2    VIVUS Inc
        16.2.1    Financial Analysis
        16.2.2    Product Portfolio
        16.2.3    Demographic Reach and Achievements
        16.2.4    Mergers and Acquisitions
        16.2.5    Certifications 
    16.3     Pfizer, Inc.
        16.3.1    Financial Analysis
        16.3.2    Product Portfolio
        16.3.3    Demographic Reach and Achievements
        16.3.4    Mergers and Acquisitions
        16.3.5    Certifications
    16.4    Novo Nordisk
        16.4.1    Financial Analysis
        16.4.2    Product Portfolio
        16.4.3    Demographic Reach and Achievements
        16.4.4    Mergers and Acquisitions
        16.4.5    Certifications
    16.5    Bayer AG
        16.5.1     Financial Analysis
        16.5.2    Product Portfolio
        16.5.3    Demographic Reach and Achievements
        16.5.4    Mergers and Acquisitions
        16.5.5    Certifications
    16.6    F Hoffmann-La Roche
        16.6.1    Financial Analysis
        16.6.2    Product Portfolio
        16.6.3    Demographic Reach and Achievements
        16.6.4    Mergers and Acquisitions
        16.6.5    Certifications
    16.7    Glaxosmithkline
        16.7.1    Financial Analysis
        16.7.2    Product Portfolio
        16.7.3    Demographic Reach and Achievements
        16.7.4    Mergers and Acquisitions
        16.7.5    Certifications
    16.8    Arena Pharmaceuticals
        16.8.1    Financial Analysis
        16.8.2    Product Portfolio
        16.8.3    Demographic Reach and Achievements
        16.8.4    Mergers and Acquisitions
        16.8.5    Certifications
    16.9    Eisai Co. Ltd
        16.9.1    Financial Analysis
        16.9.2    Product Portfolio
        16.9.3    Demographic Reach and Achievements
        16.9.4    Mergers and Acquisitions
        16.9.5    Certifications
    16.10    Takeda Pharmaceutical Company
        16.10.1    Financial Analysis
        16.10.2    Product Portfolio
        16.10.3    Demographic Reach and Achievements
        16.10.4    Mergers and Acquisitions
        16.10.5    Certifications
    16.11    Nalpropion Pharmaceuticals Inc
        16.11.1    Financial Analysis
        16.11.2    Product Portfolio
        16.11.3    Demographic Reach and Achievements
        16.11.4    Mergers and Acquisitions
        16.11.5    Certifications 
17    Asia Pacific Anti-Obesity Drugs Market – Distribution Model (Additional Insight)
    17.1     Overview 
    17.2     Potential Distributors 
    17.3     Key Parameters for Distribution Partner Assessment 
18    Key Opinion Leaders (KOL) Insights (Additional Insight)
19    Company Competitiveness Analysis (Additional Insight) 
   19.1     Very Small Companies
    19.2     Small Companies
    19.3     Mid-Sized Companies
    19.4     Large Companies
    19.5     Very Large Companies
20    Payment Methods (Additional Insight)
    20.1     Government Funded
    20.2     Private Insurance
    20.3     Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.